Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) The role of aspirin as antiaggregant therapy in primary prevention. An update
Journal Information
Vol. 153. Issue 8.
Pages 326-331 (October 2019)
Share
Share
Download PDF
More article options
Visits
2
Vol. 153. Issue 8.
Pages 326-331 (October 2019)
Review
The role of aspirin as antiaggregant therapy in primary prevention. An update
Papel de la Aspirina® como tratamiento antiagregante en prevención primaria. Puesta al día
Visits
2
Nicolás Jiménez-Garcíaa,
Corresponding author
nijimenez93@gmail.com

Corresponding author.
, Javier de la Torre Limaa, Javier García Alegríaa,b
a Servicio de Medicina Interna, Agencia Sanitaria Costa del Sol, Marbella, Málaga, Spain
b Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (3)
Table 1. Methodology of the ASCEND, ARRIVE9,10 and ASPREE11–13 studies.
Table 2. Main results of the ASCEND, ARRIVE and ASPREE studies.
Table 3. Main results of the meta-analysis of trials on primary prevention of vascular events with Aspirin® by Zheng and Roddick.14
Show moreShow less
Abstract

Aspirin indication in primary prevention has been questioned in the last ten years due to the publica-tion of several trials with neutral outcomes. In the last year, three research studies discussed in thisreview (ASCEND, ARRIVE, ASPREE) have weighed the benefit (cardiovascular events reduction) againstthe adverse effects (especially bleeding) in several situations such as general population with moderatecardiovascular risk, diabetics and elderly population. This review performs a detailed analysis of thesetrials and it also comments on a recent metanalysis that includes these projects along with others under-taken in the last 30 years. In addition, the current position of aspirin in primary prevention is establishedbased on the latest evidence reviewed.

Keywords:
Aspirin
Primary prevention
Antiaggregation
Cardiovascular events
Bleedings
Resumen

La indicación de la Aspirina®en prevención primaria ha sido puesta en duda en la última década a raízde la publicación de diversos ensayos con resultados neutros. En el último año, 3 trabajos comentados enesta revisión (ASCEND, ARRIVE y ASPREE) han ponderado el beneficio (reducción de eventos cardiovas-culares) frente a los eventos adversos (fundamentalmente hemorrágicos) en diversos escenarios comoson la población general con moderado riesgo cardiovascular, diabéticos y ancianos. La presente revisiónrealiza un análisis pormenorizado de estos 3 estudios y comenta un reciente metaanálisis que recogetanto estos trabajos como otros realizados durante los últimos 30 años. Además, se establece el actualposicionamiento de la Aspirina®en prevención primaria a la luz de la evidencia revisada.

Palabras clave:
Aspirina®
Prevención primaria
Antiagregación
Eventos cardiovasculares
Hemorragias

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos